MedTrace Logo

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT02951156 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2020-12-17

Study results available
· View outcomes & findings →

Summary

Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL

Avelumab

Investigational fully human anti-PD-L1 monoclonal antibody

BIOLOGICAL

Utomilumab

Investigational, fully human IgG2 CD 137/4-1BB agonist

BIOLOGICAL

Rituximab

CD20-directed cytolytic antibody

OTHER

Azacitidine

Antimetabolite antineoplastic agent and demethylation agent.

DRUG

Bendamustine

Alkylating drug

DRUG

Gemcitabine

Nucleoside analogue

DRUG

Oxaliplatin

Platinum-based drug

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-16
Primary Completion
2019-12-02
Completion
2019-12-02

Countries

  • United States
  • Australia
  • Belgium
  • Italy
  • Poland
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02951156 on ClinicalTrials.gov